Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib plus reduced-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
2019-004540-29Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Transfusion. Primary endpoint: MRD response after two cycles of induction therapy plus ponatinib. Started Jul 2020; status: completed.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2019-004540-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004540-29.